Business
Vividion Announces Publication in Science of Preclinical Data on Covalent Inhibitors of RAS-PI3K that Block Tumor Growth
SAN DIEGO, October 09, 2025--Science publication describes the discovery and preclinical characterization of small molecules that inhibit RAS-dependent PI3K oncogenic signaling.
About this update from Bayer Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":800,"height":241,"url":"https://media.zenfs.com/en/business-wire.com/86e1c32f21ae8a733be5b6d2dcfba3e9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MZY2Q7mvZ9TOTipApJh.cw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI4OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/86e1c32f21ae8a733be5b6d2dcfba3e9","width":800,"height":241},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/JPm8VMe_XLyMz.kFLlkb1A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE2MDA7aD00ODI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/86e1c32f21ae8a733be5b6d2dcfba3e9","width":800,"height":241}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Chemoproteomics screening platform identified novel covalent inhibitors that specifically disrupt RAS-mediated activation of the catalytic subunit of PI 3-kinase alpha (PI3Kα)","length":175,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Newly identified group of compounds shown to inhibit RAS-mutant and HER2 over-expressing tumors in vivo, particularly in combination with other RAS/MAPK inhibition, without causing hyperglycemia","length":194,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Related investigational therapy currently in Phase I clinical trial","length":67,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":436,"olType":false},{"type":"text","content":"SAN DIEGO, October 09, 2025--(BUSINESS WIRE)--Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced the publication of a manuscript in Science describing the discovery and preclinical characterization of small molecules that inhibit RAS-dependent PI3Kα oncogenic signaling by specifically blocking the interaction between RAS and PI3Kα, without disrupting homeostatic signaling.","length":494,"tagName":"p"},{"type":"text","content":"The article, "Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2" (Klebba et al., Science, Advanced Online Publication, October 2025), demonstrates the promising potential of RAS-PI3Kα inhibitors as treatments for RAS-driven cancers.","length":287,"tagName":"p"},...